Evidence map›Paper›PMID 37195382›Full record

ReviewJournal of cell communication and signaling2023

Potential of extracellular vesicles for early prediction of severity and potential risk stratification in critical inflammatory diseases.

Yuchuan Deng, Yu Zou, Xiaoshuang Song, Ailing Jiang, Mao Wang, Qin Qin, Yiran Song, Chao Yue, Dujiang Yang, Bo Yu and 2 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cell communication and signaling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yuchuan Deng *Department of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Yu Zou *Department of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Xiaoshuang SongDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Ailing JiangDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Mao WangDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Qin QinDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Yiran SongDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China.
Chao YueCenter of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Dujiang YangCenter of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Bo YuZhejiang Pushkang Biotechnology Co., Ltd, Shaoxing, Zhejiang Province, China.
Huimin LuCenter of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China. HM.Lu@scu.edu.cn.
Yu ZhengDepartment of Biotherapy，Cancer Center and State Key Laboratory of Biotherapy，West China Hospital, Sichuan University, Chengdu, 6110041, Sichuan, China. zhengyu82@scu.edu.cn.
Sichuan University · CNWest China Hospital of Sichuan University · CN

Funding

Sichuan Province Science and Technology Support Program 2018SZ0381Sichuan Province Science and Technology Support Program 21YYJC2789
6 · The paper itself

Abstract

Some acute inflammatory diseases are often exacerbated during or after hospitalization, leading to some severe manifestations like systemic inflammatory response syndrome, multiple organ failure, and high mortality. Early clinical predictors of disease severity are urgently needed to optimize patient management for better prognosis. The existing clinical scoring system and laboratory tests cannot circumvent the problems of low sensitivity and limited specificity. Extracellular vesicles (EVs) are heterogeneous nanosecretory vesicles containing various biomolecules related to immune regulation, inflammation activation, and inflammation-related complications. This review provides an overview of EVs as inflammatory mediators, inflammatory signaling pathway regulators, promoters of inflammatory exacerbation, and markers of severity and prognosis. Currently, although relevant biomarkers are clinically available or are in the preclinical research stage, searching for new markers and detection methods is still warranted, as the problems of low sensitivity/specificity, cumbersome laboratory operation and high cost still plague clinicians. In-depth study of EVs might open a door in the search for novel predictors.

Indexed as

Acute pancreatitisCritical inflammatory diseasesEarly prediction of severityExtracellular vesicleInflammation signaling

Identifiers

PMID37195382
PMCPMC10189682
OpenAlexW4376872128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.